- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 487/08 - Bridged systems
Patent holdings for IPC class C07D 487/08
Total number of patents in this class: 2123
10-year publication summary
|
110
|
114
|
122
|
136
|
132
|
185
|
194
|
202
|
193
|
144
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4761 |
95 |
| Boehringer Ingelheim International GmbH | 4480 |
40 |
| Merck Sharp & Dohme LLC | 3734 |
37 |
| Gilead Sciences, Inc. | 2249 |
36 |
| Janssen Pharmaceutica N.V. | 3142 |
34 |
| Novartis AG | 10172 |
28 |
| Astellas Pharma Inc. | 1039 |
26 |
| Genentech, Inc. | 4147 |
25 |
| F. Hoffmann-La Roche AG | 7792 |
24 |
| Hoffmann-La Roche Inc. | 3849 |
24 |
| Vertex Pharmaceuticals Incorporated | 1577 |
24 |
| Pfizer Inc. | 3422 |
23 |
| Rigel Pharmaceuticals, Inc. | 518 |
18 |
| Incyte Corporation | 1068 |
17 |
| Sanofi | 4332 |
16 |
| Astex Therapeutics Limited | 207 |
13 |
| Arvinas Operations, Inc. | 251 |
13 |
| Clarity Pharmaceuticals Limited | 70 |
13 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 3019 |
12 |
| The University of North Carolina at Chapel Hill | 2125 |
12 |
| Other owners | 1593 |